Skip to content

The Use Of FFR Guided PCI Versus Complete Revascularization and Treatment Of Infarct Related Artery Only In Patients With STEMI

Multi Centre Open Label Randomised Controlled Parallel-group Three Arm Trial To Compare The Use Of Fractional Flow Reserve (FFR) Guided and Angiographically Guided Revascularization To The Treatment Of Infarct Related Artery Only In Patients With STEMI And Multivessel Disease

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02637440
Acronym
FAIO
Enrollment
560
Registered
2015-12-22
Start date
2015-12-31
Completion date
2019-11-30
Last updated
2015-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

FFR Guided PCI, Multivessel Coronary Artery Disease, STEMI

Brief summary

In patients with ST elevation myocardial infarction (STEMI) the treatment goal is revascularization of the occluded artery with the use of primary percutaneous coronary intervention (PCI). There is a large subset of patients with STEMI who also have significant disease in arteries other than the site of occlusion, and away from the culprit artery. It is estimated that up to 50% have disease of more than 50% in the non-culprit arteries. The evidence on how to treat those patients with multi vessel disease is conflicting. Earlier large-scale studies and registries have suggested early and complete revascularization is of no benefit or even harmful. More recent studies have showed the opposite of that. The CVLPRIT study showed that early complete revascularization or preventive PCI reduced primary endpoint of a composite of all cause mortality, myocardial infarction and need for repeat revascularization. The benefit was mainly due to reduced repeat revascularization in the more intensive intervention group. The PRAMI study showed very similar results as well. The use of Fractional flow Reserve (FFR) in deciding complete revascularization has also showed conflicting results so far. A previous trial showed that FFR guided intervention post STEMI increased MACE. This was conflicted with more recent study, which showed FFR guided complete revascularization improved outcome when compared with more conservative treatment of ischaemia driven intervention. In this study, the investigators are going to assess the issue of staged revascularization guided by FFR or by angiogram, compared to the standard treatment of ischaemia driven revascularization

Detailed description

To compare the clinical outcomes measured by composite of mortality, myocardial infarction and repeat revascularization by using FFR guided and angiographically guided revascularization to the standard strategy of ischaemia driven revascularization. Participants will be allocated to three arms, first conservative group of ischaemia guided PCI, second FFR guided PCI and third angiogram guided PCI where patients where patients with more than 50% lesion will undergo revascularization.

Interventions

Patients undergo Fractional Flow measurement (FFR) followed by PCI, if the FFR is less than 0.8

PROCEDUREAngio guided PCI

Patients receive PCI without FFR measurement

Sponsors

University of Limerick
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients with STEMI and multi-vessel disease on initial angiogram. 2. Above 18 years of age 3. Able to give consent

Exclusion criteria

1. Patients with indication for CABG 2. Left main stem lesion of \>50% 3. Cardiogenic shock 4. Intractable angina during hospital admission 5. Patients with limited life expectancy 6. Patients with severe chronic kidney disease 7. Patients with contraindication to dual antiplatelet therapy 8. Patients with very complex lesions that deemed not favourable for PCI 9. Pregnancy or childbearing age

Design outcomes

Primary

MeasureTime frame
Composite of cardiovascular death, myocardial infarction and / or revascularization1 year

Secondary

MeasureTime frameDescription
Cardiovascular morality1 year
Myocardial infarction1 year
Revascularization1 yearRevascularization procedure because of symptoms and evidence of ischaemia
Heart failure1 yeardocumented episode of presentation with symptoms consistent with heart failure and evidence from echocardiogram or laboratory test consistent with the diagnosis of heart failure
Costs1 yeartotal procedural costs, hospital stay costs, medications costs.
stroke1 year

Other

MeasureTime frameDescription
Bleeding1 yearany major bleeding (TIMI 3)

Countries

Ireland

Contacts

Primary ContactThomas J Kiernan, MD
tom_kiernan@hotmail.com+35361482684
Backup ContactAbdullah S Abdullah, MBBS, MRCPI, MSc
abdalasayid@gmail.com++35361482684

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026